Rabeprazole Sodium (Page 8 of 10)

14.3 Treatment of Symptomatic GERD in Adults

Two U.S. multicenter, double-blind, placebo controlled studies were conducted in 316 adult patients with daytime and nighttime heartburn. Patients reported 5 or more periods of moderate to very severe heartburn during the placebo treatment phase the week prior to randomization. Patients were confirmed by endoscopy to have no esophageal erosions.

The percentage of heartburn free daytime and/or nighttime periods was greater with Rabeprazole Sodium Delayed-Release Tablets 20 mg compared to placebo over the 4 weeks of study in Study RAB-USA-2 (47% vs. 23%) and Study RAB-USA-3 (52% vs. 28%). The mean decreases from baseline in average daytime and nighttime heartburn scores were significantly greater for Rabeprazole Sodium Delayed-Release Tablets 20 mg as compared to placebo at week 4. Graphical displays depicting the daily mean daytime and nighttime scores are provided in Figures 2 to 5.

FIGURE 2: MEAN DAYTIME HEARTBURN SCORES RAB-USA-2

Figure 2
(click image for full-size original)

FIGURE 3: MEAN NIGHTTIME HEARTBURN SCORES RAB-USA-2

Figure 3
(click image for full-size original)

FIGURE 4: MEAN DAYTIME HEARTBURN SCORES RAB-USA-3

Figure 4
(click image for full-size original)

FIGURE 5: MEAN NIGHTTIME HEARTBURN SCORES RAB-USA-3

Figure 5
(click image for full-size original)

In addition, the combined analysis of these two studies showed Rabeprazole Sodium Delayed-Release Tablets 20 mg significantly improved other GERD-associated symptoms (regurgitation, belching, and early satiety) by week 4 compared with placebo (all p values < 0.005).

Rabeprazole Sodium Delayed-Release Tablets 20 mg also significantly reduced daily antacid consumption versus placebo over 4 weeks (p<0.001).

14.4 Healing of Duodenal Ulcers in Adults

In a U.S. randomized, double-blind, multicenter study assessing the effectiveness of 20 mg and 40 mg of Rabeprazole Sodium Delayed-Release Tablets QD versus placebo for healing endoscopically defined duodenal ulcers, 100 patients were treated for up to four weeks. Rabeprazole Sodium Delayed-Release Tablets was significantly superior to placebo in producing healing of duodenal ulcers. The percentages of patients with endoscopic healing are presented below:

TABLE 11 HEALING OF DUODENAL ULCERS PERCENTAGE OF PATIENTS HEALED
Week Rabeprazole Sodium Delayed-Release Tablets20 mg QDN=34 Rabeprazole Sodium Delayed-Release Tablets40 mg QDN=33 PlaceboN=33
*
p≤0.001 versus placebo
2 44% 42% 21%
4 79%* 91%* 39%

At Weeks 2 and 4, significantly more patients in the Rabeprazole Sodium Delayed-Release Tablets 20 and 40 mg groups reported complete resolution of ulcer pain frequency (p≤0.018), daytime pain severity (p≤0.023), and nighttime pain severity (p≤0.035) compared with placebo patients. The only exception was the Rabeprazole Sodium Delayed-Release Tablets 40 mg group versus placebo at Week 2 for duodenal ulcer pain frequency (p=0.094). Significant differences in resolution of daytime and nighttime pain were noted in both Rabeprazole Sodium Delayed-Release Tablets groups relative to placebo by the end of the first week of the study. Significant reductions in daily antacid use were also noted in both Rabeprazole Sodium Delayed-Release Tablets groups compared to placebo at Weeks 2 and 4 (p<0.001).

An international randomized, double-blind, active-controlled trial was conducted in 205 patients comparing 20 mg Rabeprazole Sodium Delayed-Release Tablets QD with 20 mg omeprazole QD. The study was designed to provide at least 80% power to exclude a difference of at least 10% between Rabeprazole Sodium Delayed-Release Tablets and omeprazole, assuming four-week healing response rates of 93% for both groups. In patients with endoscopically defined duodenal ulcers treated for up to four weeks, Rabeprazole Sodium Delayed-Release Tablets was comparable to omeprazole in producing healing of duodenal ulcers. The percentages of patients with endoscopic healing at two and four weeks are presented below:

TABLE 12 HEALING OF DUODENAL ULCERS PERCENTAGE OF PATIENTS HEALED
Week Rabeprazole Sodium Delayed-Release Tablets20 mg QDN=102 Omeprazole20 mg QDN=103 95% Confidence Interval for the Treatment Difference (Rabeprazole Sodium Delayed-Release Tablets – Omeprazole)
2 69% 61% (-6%, 22%)
4 98% 93% (-3%, 15%)

Rabeprazole Sodium Delayed-Release Tablets and omeprazole were comparable in providing complete resolution of symptoms.

14.5 Helicobacter pylori Eradication in Patients with Peptic Ulcer Disease or Symptomatic Non-Ulcer Disease in Adults

The U.S. multicenter study was a double-blind, parallel-group comparison of rabeprazole, amoxicillin, and clarithromycin for 3, 7, or 10 days vs. omeprazole, amoxicillin and clarithromycin for 10 days. Therapy consisted of rabeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily (RAC) or omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily (OAC). Patients with H. pylori infection were stratified in a 1:1 ratio for those with peptic ulcer disease (active or a history of ulcer in the past five years) [PUD] and those who were symptomatic but without peptic ulcer disease [NPUD], as determined by upper gastrointestinal endoscopy. The overall H. pylori eradication rates, defined as negative 13 C-UBT for H. pylori ≥ 6 weeks from the end of the treatment are shown in the following table. The eradication rates in the 7-day and 10-day RAC regimens were found to be similar to 10-day OAC regimen using either the Intent-to-Treat (ITT) or Per-Protocol (PP) populations. Eradication rates in the RAC 3-day regimen were inferior to the other regimens.

TABLE 13 HELICOBACTER PYLORI ERADICATION AT ≥ 6 WEEKS AFTER THE END OF TREATMENT
Treatment GroupPercent (%) of Patients Cured(Number of Patients) Difference(RAC-OAC)[95% Confidence Interval]
*
The 95% confidence intervals for the difference in eradication rates for 7-day RAC minus 10-day RAC are (-9.3, 6) in the PP population and (-9, 7.5) in the ITT population.
Patients were included in the analysis if they had H. pylori infection documented at baseline, defined as a positive 13 C-UBT plus rapid urease test or culture and were not protocol violators. Patients who dropped out of the study due to an adverse event related to the study drug were included in the evaluable analysis as failures of therapy.
Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and took at least one dose of study medication. All dropouts were included as failures of therapy.
7-day RAC * 10-day OAC
Per Protocol 84.3%(N=166) 81.6%(N=179) 2.8[-5.2, 10.7]
Intent-to-Treat 77.3%(N=194) 73.3%(N=206) 4[-4.4, 12.5]
10-day RAC * 10-day OAC
Per Protocol 86%(N=171) 81.6%(N=179) 4.4[-3.3, 12.1]
Intent-to-Treat 78.1%(N=196) 73.3%(N=206) 4.8[-3.6, 13.2]
3-day RAC 10-day OAC
Per Protocol 29.9%(N=167) 81.6%(N=179) -51.6[-60.6, -42.6]
Intent-to-Treat 27.3%(N=187) 73.3%(N=206) -46[-54.8, -37.2]

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.